GP120

GP120

GP120 Overview

Molecule Name
HIV envelope protein gp120
Synonyms
GP120,GP120-CN54
Drug Development Progress
Drugs in Clinical Trials14
Approved Drugs2
Highest Development StageApproved
Target Synonym
HIV Envelope Protein gp120
Background
Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Zinlirvimab10-1074; 10-1074-LS; GS-2872Phase 2 ClinicalThe Rockefeller University
HIV Infections; Acquired Immunodeficiency Syndrome
Details
PGT121.414.LSVRC-HIVMAB0107-00-ABPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)
HIV Infections
Details
PGT-121PGT-121Phase 2 ClinicalInternational Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And Harvard
HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral
Details
Teropavimab3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423Phase 2 ClinicalThe Rockefeller University
HIV Infections; Acquired Immunodeficiency Syndrome
Details
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung)Phase 1 ClinicalPolymun Scientific Gmbh
HIV Infections
Details
PDPHV-201401PDPHV-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)
HIV Infections
Details
ElipovimabGS-9722Phase 1 ClinicalGilead Inc
HIV Infections
Details
VRC-HIVAAV070-00-GTAAV8-VRC07Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)
HIV Infections
Details
Microbicide Monoclonal Antibody Triple Combination (Polymun)Phase 1 Clinical
HIV Infections
Details
env (A, B, C, A/E)/gag DNA Vaccine(NIAID)PD-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)
HIV Infections
Details
Vrc-Hivmab0121-00-AbCAP256J3LSPhase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)
HIV Infections
Details
FB-1002(Frontier Biotechnologies)FB-1002(前沿生物)Phase 1 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Coronavirus Disease 2019 (COVID-19)
Details
DS-003DS-003; BMS-793Phase 1 ClinicalBristol-Myers Squibb Company
HIV Infections; Neoplasms
Details
A-1801A-1801ClinicalWuhan BioRaid Biotechnology Co Ltd
HIV Infections
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Radha-108ApprovedBiomix NetworkReceptol
HIV Infections
Details
Fostemsavir TromethamineBMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrugApprovedBristol-Myers Squibb CompanyRukobiaUnited StatesHIV InfectionsViiv Healthcare Co2020-07-02
HIV Infections
Details